Eliglustat
Eliglustat, sold under the brand name Cerdelga, is a medication used for the treatment of Gaucher's disease. It was discovered at the University of Michigan, developed by Genzyme Corp, and was approved by the FDA in August 2014. Commonly used as the tartrate salt, the compound is believed to work by inhibition of glucosylceramide synthase. According to an article in Journal of the American Medical Association the oral substrate reduction therapy resulted in "significant improvements in spleen volume, hemoglobin level, liver volume, and platelet count" in untreated adults with Gaucher disease Type 1.
Eliglustat - Wikipedia Jump to content From Wikipedia, the free encyclopedia Chemical compound Pharmaceutical compound Eliglustat Clinical data Trade names Cerdelga AHFS / Drugs.com Monograph MedlinePlus a618038 License data US   DailyMed :  Eliglustat Routes of administration By mouth ATC code A16AX10  ( WHO )  Legal status Legal status AU :   S4 (Prescription only) [ 1 ] CA :  ℞-only [ 2 ] [ 3 ] UK :   POM (Prescription only) [ 4 ] US :   ℞-only [ 5 ] EU :  Rx-only [ 6 ] Identifiers IUPAC name N -[(1
saved by
related reading
- New Genzyme pill will cost patients $310,250 a year - The Boston Globeweb.archive.org
- Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher diseasesanofi.com
- A new brain‐penetrant glucosylceramide synthase inhibitor as potential Therapeutics for Gaucher diseasepmc.ncbi.nlm.nih.gov
- Lactosylceramideen.wikipedia.org
- UGCG and the glycosphingolipid rheostat: a metabolic checkpoint governing immune activation and tumor immune evasion | Signal Transduction and Targeted Therapynature.com
- PDB101: Molecule of the Month: PROTACs and Molecular Glue Degraderspdb101.rcsb.org
- Targeting UGCG overcomes resistance to lysosomal autophagy inhibitionpmc.ncbi.nlm.nih.gov
- Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birthpmc.ncbi.nlm.nih.gov
- Glucosylceramide flippases contribute to cellular glucosylceramide homeostasispmc.ncbi.nlm.nih.gov
- Reconstitution of Glucosylceramide Flip-Flop across Endoplasmic Reticulum: IMPLICATIONS FOR MECHANISM OF GLYCOSPHINGOLIPID BIOSYNTHESISpmc.ncbi.nlm.nih.gov
- the drug landscapegenome-browser-eight.vercel.app
- Elicit: AI for scientific researchelicit.org